- Home
- VRAX vs ATXG Comparison
VRAX vs ATXG Comparison
Compare VRAX & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- ATXG
- Stock Information
- Founded
- VRAX 2013
- ATXG 2014
- Country
- VRAX United Kingdom
- ATXG China
- Employees
- VRAX N/A
- ATXG N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ATXG Professional Services
- Sector
- VRAX Health Care
- ATXG Consumer Discretionary
- Exchange
- VRAX Nasdaq
- ATXG Nasdaq
- Market Cap
- VRAX 5.9M
- ATXG 5.4M
- IPO Year
- VRAX 2022
- ATXG N/A
- Fundamental
- Price
- VRAX $1.14
- ATXG $0.77
- Analyst Decision
- VRAX Strong Buy
- ATXG
- Analyst Count
- VRAX 1
- ATXG 0
- Target Price
- VRAX $3.00
- ATXG N/A
- AVG Volume (30 Days)
- VRAX 123.9K
- ATXG 5.8K
- Earning Date
- VRAX 02-05-2025
- ATXG 02-14-2025
- Dividend Yield
- VRAX N/A
- ATXG N/A
- EPS Growth
- VRAX N/A
- ATXG N/A
- EPS
- VRAX N/A
- ATXG N/A
- Revenue
- VRAX $84,872.00
- ATXG $4,549,310.00
- Revenue This Year
- VRAX $5,169.18
- ATXG N/A
- Revenue Next Year
- VRAX $66.97
- ATXG N/A
- P/E Ratio
- VRAX N/A
- ATXG N/A
- Revenue Growth
- VRAX 7.03
- ATXG N/A
- 52 Week Low
- VRAX $0.60
- ATXG $0.49
- 52 Week High
- VRAX $9.00
- ATXG $1.18
- Technical
- Relative Strength Index (RSI)
- VRAX 34.78
- ATXG 41.97
- Support Level
- VRAX $1.10
- ATXG $0.81
- Resistance Level
- VRAX $1.35
- ATXG $0.89
- Average True Range (ATR)
- VRAX 0.09
- ATXG 0.06
- MACD
- VRAX 0.00
- ATXG -0.01
- Stochastic Oscillator
- VRAX 19.44
- ATXG 11.21
Stock Price Comparison Chart: VRAX vs ATXG
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.